H2 2026 Earnings
Financial report interval: 2025.12.30 - 2026.06.30
Overview: Radiopharm Theranostics(RADX) the Revenue is 994.35 K (-32.27%), Beat estimate;the EBIT is -20.67 M (-70.04%), Miss estimate;the EPS is -1.53 (-5.59%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B32.27%
0.00B61.64%
+0.00B29.37%
EBITMiss expectations
-0.02B70.04%
-0.02B41.82%
-0.00B28.22%
EPSMiss expectations
-1.52955.59%
-1.291810.82%
-0.237716.41%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf